McKesson Reports Fiscal 2013 Third-Quarter Results January 31, 2013

McKesson News Release:

McKesson Reports Fiscal 2013 Third-Quarter Results January 31, 2013		Share on emailShare on printShare on stumbleuponShare on diggShare on twitterShare on facebookMore Sharing Services
McKesson Corporation (NYSE: MCK) today reported that revenues for the third quarter ended December 31, 2012 were $31.2 billion, up 1% compared to $30.8 billion a year ago. Revenues of $31.2 billion for the third quarter, up 1%. Third-quarter GAAP earnings per diluted share of $1.24, up 3%. Third-quarter Adjusted Earnings per diluted share of $1.41, up 1%. Board of Directors authorized an additional $500 million share repurchase program. Fiscal 2013 Outlook:  Adjusted Earnings per diluted share of $7.10 to $7.30. SAN FRANCISCO, January 31, 2013 – McKesson Corporation (NYSE: MCK) today reported that revenues for the third quarter ended December 31, 2012 were $31.2 billion, up 1% compared to $30.8 billion a year ago.  On the basis of U.S. generally accepted accounting principles (“GAAP”), third-quarter earnings per diluted share was $1.24 compared to $1.20 a year ago.   Third-quarter Adjusted Earnings per diluted share was $1.41, up 1% compared to $1.40 a year ago.   For the first nine months of the fiscal year, McKesson generated cash from operations of $276 million, and ended the quarter with cash and cash equivalents of $2.7 billion.  During the first nine months of the fiscal year, the company paid $147 million in dividends, had internal capital spending of $268 million and spent $577 million on acquisitions.   The company also repurchased $360 million of its common stock during the third quarter.   Distribution Solutions revenues were up 1% in the third quarter, driven mainly by growth in our U.S. pharmaceutical direct distribution and services business and growth in our Medical-Surgical distribution business.     Canadian revenues, on a constant currency basis, increased 3% for the third quarter.  Including the favorable currency impact of 3%, Canadian revenues increased 6% for the third quarter.   Medical-Surgical distribution and services revenues were up 15% for the third quarter, driven by market growth, new customers, acquisitions and one additional sales day. In the third quarter, Distribution Solutions GAAP operating profit was $525 million and GAAP operating margin was 1.73%.  Third-quarter adjusted operating profit was $569 million and the adjusted operating margin was 1.87%.  Distribution Solutions third-quarter segment results include a $40 million pre-tax charge related to a legal dispute in our Canadian business. Technology Solutions revenues were flat in the third quarter compared to the prior year.  GAAP operating profit was $79 million for the third quarter and GAAP operating margin was 9.56%.  Adjusted operating profit was $98 million for the third quarter and adjusted operating margin was 11.86%.  Technology Solutions third-quarter segment results were impacted by revenue deferral in our international business. “Our full year view of the operating performance in our Distribution Solutions segment is now better than our original expectations, and our full year view of the operating performance in the primary businesses in Technology Solution remains unchanged,” said John H. Hammergren, chairman and chief executive officer.   “This operating strength is offset by the charge in our Canadian business and revenue deferral in our international technology business, and as a result we are updating our previous outlook for the fiscal year and now expect Adjusted Earnings per diluted share of $7.10 to $7.30 for the fiscal year ending March 31, 2013.” Fiscal Year 2013 Outlook McKesson expects Adjusted Earnings per diluted share of $7.10 to $7.30 for the fiscal year ending March 31, 2013, which excludes the following GAAP items: Amortization of acquisition-related intangible assets of approximately 55 cents per diluted share in Fiscal 2013.  Acquisition expenses and related adjustments expected to add approximately 13 cents per diluted share, including the impact of the $81 million pre-tax gain on business combination related to the acquisition of the remaining 50% ownership in McKesson’s corporate headquarters building completed during the first quarter. Litigation reserve adjustments of approximately 15 cents per diluted share. Adjusted Earnings McKesson separately reports financial results on the basis of Adjusted Earnings.  Adjusted Earnings is a non-GAAP financial measure defined as GAAP income from continuing operations, excluding amortization of acquisition-related intangible assets, acquisition expenses and related adjustments, and certain litigation reserve adjustments.  A reconciliation of McKesson’s financial results determined in accordance with GAAP to Adjusted Earnings is provided in Schedules 2, 3 and 4 of the financial statement tables included with this release.  Risk Factors Except for historical information contained in this press release, matters discussed may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied.  These statements may be identified by their use of forward-looking terminology such as “believes”, “expects”, “anticipates”, “may”, “will”, “should”, “seeks”, “approximately”, “intends”, “plans”, “estimates” or the negative of these words or other comparable terminology.  The discussion of financial trends, strategy, plans or intentions may also include forward-looking statements.  It is not possible to predict or identify all such risks and uncertainties; however, the most significant of these risks and uncertainties are described in the company’s Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission and include, but are not limited to: material adverse resolution of pending legal proceedings; changes in the U.S. healthcare industry and regulatory environment; changes in the Canadian healthcare industry and regulatory environment; competition; substantial defaults in payment or a material reduction in purchases by, or the loss of, a large customer or group purchasing organization; the loss of government contracts as a result of compliance or funding challenges; public health issues in the U.S. or abroad; implementation delay, malfunction, failure or breach of internal information systems; the adequacy of insurance to cover property loss or liability claims; the company’s failure to attract and retain customers for its software products and solutions due to integration and implementation challenges, or due to an inability to keep pace with technological advances; the company’s proprietary products and services may not be adequately protected, and its products and solutions may be found to infringe on the rights of others; system errors or failure of our technology products and solutions to conform to specifications; disaster or other event causing interruption of customer access to data residing in our service centers; the delay or extension of our sales or implementation cycles for external software products; changes in circumstances that could impair our goodwill or intangible assets; foreign currency fluctuations or disruptions to our foreign operations; new or revised tax legislation or challenges to our tax positions; the company’s ability to successfully identify, consummate and integrate strategic acquisitions; general economic conditions, including changes in the financial markets that may affect the availability and cost of credit to the company, its customers or suppliers; and changes in accounting principles generally accepted in the United States of America.  The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made.  Except to the extent required by law, the company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events. The company has scheduled a conference call for 5:00 PM ET.  The dial-in number for individuals wishing to participate on the call is 719-234-7317.  Erin Lampert, vice president, Investor Relations, is the leader of the call, and the password to join the call is ‘McKesson’.  A replay of this conference call will be available for five calendar days.   The dial-in number for individuals wishing to listen to the replay is 888-203-1112 and the pass code is 8164902.  A webcast of the conference call will also be available live and archived on the company’s Investor Relations website atwww.mckesson.com/investors.  Shareholders are encouraged to review SEC filings and more information about McKesson, which are located on the company’s website.  About McKesson McKesson Corporation, currently ranked 14th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better.  We partner with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting.  McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services.  For more information, visithttp://www.mckesson.com. Tables and full-text of earnings release also available for viewing and download in PDF format:McKesson Reports Fiscal 2013 Third-Quarter Results (PDF)